TAKEDA PHARMACEUTICALS AMERICA INC

Lobbying client · District of Columbia · filed 2025 to 2026

$6,040,000 Reported spend

6 Filings counted

1 Firms hired

8 Bills named

Spend is reported income plus in-house expenses across 6 filings. 1 further filing on this record was restated by a later amendment and is left out of every total here. Everything on this page is grouped by the client's LDA id (160416), not by name.

Firms hired 1

TAKEDA PHARMACEUTICALS AMERICA, INC. $6,040,000 6 filings

Bills named in these filings 8

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

6 filings
S 832
EPIC Act of 2025

6 filings
HR 946
ORPHAN Cures Act

5 filings
HR 4229
To amend the Impoundment Control Act of 1974 to require prior approval from Congress before the Comptroller G…

4 filings
HR 2214
DRUG Act

3 filings
HR 1476
PLASMA Act

2 filings
S 694
PLASMA Act

2 filings
HR 2528
Association Health Plans Act

1 filing

Reported by year 2 years

2026 $2,020,000 2 filings
2025 $4,020,000 4 filings

Issues lobbied 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 6

HOUSE OF REPRESENTATIVES 6
SENATE 6
Centers For Medicare and Medicaid Services (CMS) 4
Office of Management & Budget (OMB) 1
U.S. International Trade Commission (ITC) 1
U.S. Trade Representative (USTR) 1

Recent filings 7 total

Q2

TAKEDA PHARMACEUTICALS AMERICA, INC.

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $610,000 expenses · posted Jul 20, 2026

View → Q1

TAKEDA PHARMACEUTICALS AMERICA, INC.

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $1,410,000 expenses · posted Apr 20, 2026

View → Q4

TAKEDA PHARMACEUTICALS AMERICA, INC.

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $590,000 expenses · posted Jan 20, 2026

View → Q3

TAKEDA PHARMACEUTICALS AMERICA, INC.

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $1,370,000 expenses · posted Oct 20, 2025

View → 2A

TAKEDA PHARMACEUTICALS AMERICA, INC.

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $1,570,000 expenses · posted Aug 26, 2025

View → Q2

TAKEDA PHARMACEUTICALS AMERICA, INC. Amended

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $1,520,000 expenses · posted Jul 21, 2025

View → Q1

TAKEDA PHARMACEUTICALS AMERICA, INC.

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $490,000 expenses · posted Apr 22, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.